NVO Stock Risk & Deep Value Analysis
Novo Nordisk A/S
Healthcare • Drug Manufacturers - General
DVR Score
out of 10
What You Need to Know About NVO Stock
We analyzed Novo Nordisk A/S using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran NVO through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
NVO Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is accelerated market share loss to Eli Lilly's superior GLP-1 drugs, leading to Novo Nordisk's projected 5-13% sales decline materializing or worsening. This could erode profitability and investor confidence, preventing the stock from reaching its current analyst price targets.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Medium
Competitive
High
Execution
Low
Regulatory
Medium
Red Flags
- ⚠
Analyst projections for lower-than-expected GLP-1 revenue growth for Q1 2026.
- ⚠
Eli Lilly seizing meaningful market share with superior GLP-1 drugs, projecting 20-25% revenue growth for 2026 while NVO braces for a sales decline.
- ⚠
Reliance on the GLP-1 franchise amidst intensifying competition.
Upcoming Risk Events
- 📅
Q1 2026 earnings miss and downward guidance due to competitive pressure
- 📅
Further market share losses to Eli Lilly's Zepbound/Mounjaro
- 📅
Negative results from late-stage clinical trials for pipeline assets
- 📅
Increased regulatory scrutiny or pricing pressures on GLP-1 drugs
When to Reconsider
- 🚪
Exit if Q1 2026 earnings report confirms significant revenue decline and poor forward guidance, especially beyond the 5-13% projection.
- 🚪
Sell if competitive news indicates a further widening of the efficacy/safety gap with rival GLP-1s, leading to sustained market share erosion.
- 🚪
Exit if the stock breaks below $36.00 and shows no signs of support, indicating a breach of technical and fundamental valuation floors.
Unlock NVO Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Novo Nordisk A/S (NVO) Do?
Market Cap
$1.09T
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
78,554
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Visit Novo Nordisk A/S WebsiteInvestment Thesis
Novo Nordisk is a high-quality, fundamentally strong pharmaceutical leader in the massive and growing diabetes and obesity markets. Its robust GLP-1 franchise, coupled with ongoing R&D, strategic partnerships, and consistent capital allocation, positions it for continued long-term stability and moderate growth. While 10x growth in 3-5 years is unrealistic for a company of this size, NVO offers a defensive play with strong cash flows and potential for steady appreciation.
Is NVO Stock Undervalued?
Unlock the full AI analysis for NVO
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
NVO Price Targets & Strategy
12-Month Target
$47.25
Bull Case
$65.00
Bear Case
$36.00
Valuation Basis
Based on a conservative 13.5x forward P/E applied to estimated stable 2026 EPS of $3.50 (derived from 2025 net profit $15.48B/4.465B shares, adjusting for competitive pressures).
Entry Strategy
Dollar-cost average on dips below $40.00, leveraging NVO's strong long-term fundamentals despite near-term competitive headwinds. Consider accumulation near its 50-day SMA if it trends lower.
Exit Strategy
Take profit at target $47.25 and monitor competitive landscape. Consider a stop-loss order if price breaks below $36.00 (analyst low target) on significant volume, indicating further market share erosion.
Portfolio Allocation
1-3% for moderate risk tolerance, acknowledging the established company profile and limited short-term exponential growth.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is NVO Financially Healthy?
Valuation
P/E Ratio
10.68
Forward P/E
12.00
PEG Ratio
8.96
Profitability
Gross Margin
80.98%
Operating Margin
41.30%
Net Margin
33.14%
Return on Equity
61.10%
Revenue Growth
6.43%
EPS
$23.03
Balance Sheet
Current Ratio
0.80
Quick Ratio
0.57
Debt/Equity
0.67
Other
Beta (Volatility)
1.72
Dividend Yield
4.65%
Does NVO Have a Competitive Moat?
Sign in to unlockMoat Rating
🏰 Wide
Moat Trend
Eroding
Moat Sources
4 Identified
Novo Nordisk's moat remains wide due to its pioneering role and established market presence with GLP-1s, coupled with extensive IP. However, the emergence of highly effective and potentially superior competitors like Eli Lilly, along with a crowded pipeline of new entrants, is actively eroding its competitive edge and requiring continuous innovation to maintain its lead.
Moat Erosion Risks
- •Development of 'me-too' or 'better-than' GLP-1/GIP/triple agonists by competitors (e.g., Eli Lilly, Viking Therapeutics) that gain significant market share.
- •Patent expirations or challenges to key GLP-1 compounds in the long term, opening the door to generics.
- •Regulatory changes or increased scrutiny on drug pricing that could impact profitability.
NVO Competitive Moat Analysis
Sign up to see competitive advantages
NVO Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. While NVO is a well-regarded company, specific social media discussions often focus on GLP-1 drug access, efficacy, and side effects, rather than specific investment sentiment for NVO itself.
Institutional Sentiment
Neutral. Multiple analysts rated 'Hold' over the past month, with BMO Capital lowering its price target due to Wegovy pill revenue concerns, indicating some caution despite overall positive long-term outlook.
Insider Activity (Form 4)
The company repurchased 11,007,992 B shares since February 4, 2026, totaling DKK 2.835 billion, demonstrating management confidence in intrinsic value and a commitment to shareholder returns. No specific CEO/CFO activity detailed.
Options Flow
Normal options activity; no specific data provided to indicate unusual institutional positioning, suggesting typical hedging or speculative activity rather than significant directional bets.
Earnings Intelligence
Next Earnings
2026-05-06
Surprise Probability
Medium
Historical Earnings Pattern
Historically, NVO has often met or slightly exceeded expectations, leading to moderate positive stock reactions. However, recent competitive headwinds suggest a higher potential for a negative reaction if results or guidance disappoint.
Key Metrics to Watch
Competitive Position
Top Competitor
LLY
Market Share Trend
Losing ground in the GLP-1 space to Eli Lilly with its Mounjaro/Zepbound, which are perceived as having superior efficacy. While NVO remains dominant, its market share is under pressure.
Valuation vs Peers
NVO is likely trading at a modest premium compared to some mature pharmaceutical peers due to its dominant GLP-1 franchise, but potentially at a discount to high-growth biotech. Compared to Eli Lilly (LLY), NVO's growth is projected to be lower, which could lead to a relative valuation discount.
Competitive Advantages
- •Established global leadership and brand recognition in diabetes and obesity care
- •Extensive R&D and manufacturing infrastructure for biologics
- •Strong patent portfolio and intellectual property surrounding semaglutide
- •Broad distribution network and established patient/physician relationships
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive NVO Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Announcement (May 6, 2026)
- •Continued rollout and uptake of Wegovy HD and oral Wegovy across US pharmacies
Medium-Term (6-18 months)
- •Further integration of AI in drug discovery and manufacturing via OpenAI partnership
- •Expansion into new therapeutic areas or geographies for GLP-1 agonists beyond diabetes/obesity
- •Pipeline advancements for non-GLP-1 assets
Long-Term (18+ months)
- •Potential for next-generation weight-loss drugs with superior efficacy or safety profiles
- •Consolidation of market leadership in chronic disease management through diversified portfolio
- •Leveraging AI for accelerated R&D cycles
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for NVO?
- ✓
Acceleration in the growth of new product launches or pipeline success beyond GLP-1s.
- ✓
Evidence of effective counter-strategies against Eli Lilly, such as new formulations or combinations that regain market share.
- ✓
Sustained positive free cash flow generation and continued share buybacks.
Bull Case Analysis
See what could go right with Premium
Competing with NVO
See how Novo Nordisk A/S compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Novo Nordisk A/S NVO | $1.1T | 1.4 | 10.7 | — | 33.1% | 6.4% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Novo Nordisk A/S Makes Money
Novo Nordisk is a global healthcare company specializing in the discovery, development, manufacturing, and marketing of pharmaceutical products, primarily for diabetes and other serious chronic diseases like obesity, hemophilia, and growth hormone-related disorders. They generate revenue by selling prescription drugs to patients through healthcare providers, pharmacies, and distributors worldwide. Their business model thrives on innovation in biologics and proprietary drug development, creating high-value treatments for large and growing patient populations.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Novo Nordisk A/S (NVO)?
As of April 16, 2026, Novo Nordisk A/S has a DVR Score of 1.4 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Novo Nordisk A/S?
Novo Nordisk A/S's market capitalization is approximately $1.1T. The company operates in the Healthcare sector within the Drug Manufacturers - General industry.
What ticker symbol does Novo Nordisk A/S use?
NVO is the ticker symbol for Novo Nordisk A/S. The company trades on the NYQ.
What is the risk level for NVO stock?
Our analysis rates Novo Nordisk A/S's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of NVO?
Novo Nordisk A/S currently has a price-to-earnings (P/E) ratio of 10.7. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Does Novo Nordisk A/S pay a dividend?
Yes, Novo Nordisk A/S pays a dividend with a current yield of approximately 4.65%.
Is Novo Nordisk A/S's revenue growing?
Novo Nordisk A/S has reported revenue growth of 6.4%. The company is growing at a moderate pace.
Is NVO stock profitable?
Novo Nordisk A/S has a profit margin of 33.1%. This indicates strong profitability.
How often is the NVO DVR analysis updated?
Our AI-powered analysis of Novo Nordisk A/S is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 16, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for NVO (Novo Nordisk A/S) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.